Topical corticosteroids remain a cornerstone of atopic dermatitis care, but steroid phobia and a growing roster of nonsteroidal agents are reshaping how clinicians use them. On this episode of Don’t Be Rash, host Andrew C. Krakowski, MD, talks with pediatric dermatologist Lawrence Eichenfield, MD, about where steroids fit today. Eichenfield separates true topical steroid withdrawal, which he describes as rare, from the widespread fear fueled by social media. He explains how US topical steroid potency classes (class 1 through class 7) rest on the vasoconstrictor assay, why a drug’s percentage does not predict its strength, and how vehicle changes potency, as with mometasone cream versus ointment. The conversation also covers practical dosing for topical corticosteroids: once-daily versus twice-daily application, prescribing by volume, fingertip units, and when maintenance use should give way to a nonsteroid. Eichenfield reviews how skin thickness and anatomy guide potency selection, including atrophic skin, the hands and feet, and lichen sclerosus. He also outlines nonsteroidal options for atopic dermatitis, including PDE4 inhibitors, tapinarof, ruxolitinib, and delgocitinib for chronic hand eczema, and how lessons from the tacrolimus and pimecrolimus era apply to newer agents.